Eupraxia Pharmaceuticals (EPRX) EBITDA (2023 - 2026)
Eupraxia Pharmaceuticals (EPRX) posted quarterly EBITDA of -$12.6 million for Q1 2026, down 86.87% year-over-year from -$96.3 million in Q1 2025, and up 24.27% quarter-over-quarter from -$16.7 million in Q4 2025.
Eupraxia Pharmaceuticals (EPRX) EBITDA (2023 - 2026) Analysis & Trends
Eupraxia Pharmaceuticals (EPRX) has reported EBITDA for 4 consecutive years, with -$12.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, EBITDA fell 86.87% year-over-year to -$12.6 million; the TTM figure through Mar 2026 stood at -$44.4 million (down 73.93% YoY), while the FY2025 annual figure was $4.8 million, down 14.35% from the prior year.
- EBITDA rose to -$12.6 million in Q1 2026 per EPRX's latest filing, from -$16.7 million in the prior quarter.
- Across five years, EBITDA topped out at -$4.2 million in Q1 2023 and bottomed at -$16.7 million in Q4 2025.
- Historically, EBITDA has averaged -$8.2 million across 4 years, with a median of -$6.5 million in 2024.
- On a YoY basis, EBITDA climbed as much as 4.5% in 2025 and fell as far as 163.96% in 2025.
- Eupraxia Pharmaceuticals' EBITDA stood at -$4.2 million in 2023, then slumped by 48.87% to -$6.3 million in 2024, then plunged by 163.96% to -$16.7 million in 2025, then gained by 24.27% to -$12.6 million in 2026.
- Business Quant data shows EPRX's EBITDA at -$12.6 million in Q1 2026, -$16.7 million in Q4 2025, and -$6.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 493.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 325.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2.33 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 133.12 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 231.44 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.55 Mn |
| 10 | Eupraxia Pharmaceuticals | 381.11 Mn | 379.51 Mn | - | -12.64 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -12.64 Mn |
| Dec 31, 2025 | -16.69 Mn |
| Sep 30, 2025 | -6.37 Mn |
| Jun 30, 2025 | -8.74 Mn |
| Mar 31, 2025 | -6.76 Mn |
| Dec 31, 2024 | -6.32 Mn |
| Sep 30, 2024 | -5.99 Mn |
| Mar 31, 2024 | -6.47 Mn |
| Mar 31, 2023 | -4.25 Mn |